QuEChERS结合超高效液相色谱-串联质谱法检验腐败血中4-甲基甲卡西酮和甲卡西酮

建立了腐败血中4-甲基甲卡西酮和甲卡西酮的超高效液相色谱-三重四级杆串联质谱(UPLC-MS/MS)检测方法。腐败血样品经乙腈水混合溶液(乙腈:水=4:1,V/V)提取,无水MgSO_4脱水和C_(18)吸附剂净化。选用Waters BEH C_(18)色谱柱分离,0.1%甲酸-水(5 mmol/L乙酸铵)和乙腈作为流动相进行梯度洗脱,电喷雾电离,正离子(ESI~+)模式扫描,多反应监测(MRM)模式检测。4-甲基甲卡西酮和甲卡西酮在0.5～100 ng/mL范围内线性关系良好(R~2≧0.9993),检出限(S/N=3)分别为0.01 ng/mL(4-甲基甲卡西酮)和0.03 ng/mL(甲卡西酮),定量限(S/N=10)分别为0.1 ng/mL(4-甲基甲卡西酮)和0.5 ng/mL(甲卡西酮)。     

QuEChERS-高效液相色谱-串联质谱法测定植物源食品中环磺酮残留

建立了高效液相色谱-串联质谱法(HPLC-MS/MS)测定植物源食品中环磺酮残留量的分析方法.样品经改进的QuEChERS方法一步完成萃取净化,经酸化乙腈(含0.1％(V/V)甲酸的乙腈)提取,经石墨化碳黑(GCB)净化,提取液经离心后直接过膜上机检测.HPLC-MS/MS方法以0.1％(V/V)甲酸-乙腈为流动相,在0.25 mL/min流速下梯度洗脱,采用C18色谱柱进行液相色谱分离,电喷雾正离子电离(ESI+),多重反应监测模式(MRM)检测,基质匹配外标法进行定量分析.结果表明,在10种基质(玉米、大米、小麦、葡萄、苹果、葡萄干、枸杞、西红柿、黄瓜、白菜)中,环磺酮在0.5 ～ 100.0 ng/mL范围内线性关系良好,相关系数均大干0.996;方法定量限(S/N≥10)为1.0 μg/kg;在1.0,2.0和10.0μg/kg添加水平下,环磺酮的平均回收率为82.0％ ～111.8％,相对标准偏差为3.0％～14.9％.本方法高效快捷,灵敏度、准确度和精密度均符合农药残留检测要求.     

高效液相色谱-三重四极杆/复合离子阱质谱测定大鼠血浆中11种合成大麻素

建立并验证了一种用于定量检测大鼠血浆中11种合成大麻素(SCs)的高效液相色谱-串联质谱(HPLC-MS/MS)方法。选择Waters UPLC HSS T3(150 mm×2.1 mm,1.8μm)色谱柱,以乙腈为蛋白沉淀剂(血浆∶乙腈=1∶9,V/V),实现了11种目标物质的色谱分离和检测。方法学验证数据表明,本方法在0.05～10 ng/mL范围内具有良好线性(R²>0.991),基质效应为69.5%～119.0%,回收率为43.8%～131.5%,相对标准偏差为4.0%～28.3%,定量限为0.05～1 ng/mL。本方法适用于血浆中SCs的定性定量检测。     

高效液相色谱-串联质谱法测定兔血浆中吡喹酮

建立了高效液相色谱-串联质谱法测定兔血浆中吡喹酮浓度。血浆样品经乙腈沉淀蛋白,以Waters XBridge C18柱(2.1×50 mm,3.5μm)进行色谱分离,流动相为乙腈-体积分数0.1%甲酸溶液,梯度洗脱分离,三重四级杆质谱仪进行电喷雾离子化和正离子多离子反应监测模式检测吡喹酮。吡喹酮在0.8~2000.0 ng/mL范围内线性关系良好,相关系数为0.9983,检出限为0.01 ng/mL,在加样量为1600.0,160.0,2.5 ng/mL的血浆样品中,吡喹酮的相对回收率为83.8%~104.8%,提取回收率为79.5%~96.5%,日内和日间RSD均小于6.4%。方法可用于吡喹酮血药浓度的测定。     

超高效液相色谱串联质谱法同时快速检验全血中扎来普隆及其代谢产物

建立了全血中扎来普隆及其代谢产物5-氧扎来普隆和脱乙基扎来普隆超高效液相色谱-三重四级杆质谱(UPLC-TQ/MS)快速检验方法.采用改良后的QuEChERS前处理方法,全血样品用0.1％甲酸-乙腈提取,经无水MgSO4脱水净化,Waters BEH C18色谱柱分离,0.1％甲酸和0.1％甲酸-乙腈进行梯度洗脱.采用电喷雾电离,正离子(ESI+)模式扫描,多反应监测(MRM)模式检测.扎来普隆及其代谢产物在0.5～100 ng/mL范围内线性关系良好(R2≥0.997),回收率为92.0％～100.1％,相对标准偏差为1.9％ ～5.3％,方法检出限(S/N=3)均为0.05 ng/mL,定量限(S/N=I0)在0.1～0.5 ng/ mL范围内.     

液相色谱-串联质谱法同时测定动物血浆中21种霉菌毒素或其代谢物残留

建立了同时检测动物血浆中黄曲霉毒素B1等21种霉菌毒素或其代谢物残留的液相色谱-串联质谱方法.动物血浆样品中加入0.1％甲酸-乙腈溶液、NaCl和无水MgSO4进行萃取,无水MgSO4和C18,PSA,A-AL对提取液进行脱水净化,经浓缩、复溶和离心后,再进行测定.采用反相C18色谱柱分离,以0.1％甲酸-0.5 mmol/L乙酸铵溶液和0.1％甲酸-甲醇溶液作为流动相进行梯度洗脱,采用电喷雾离子源(ESI)多反应监测离子模式(MRM)进行检测,基质标准曲线外标法进行定量分析,线性范围在0.05 ～ 100 ng/mL之间,方法的定量限为0.05 ～0.5 ng/mL.在高、中、低3个添加浓度水平下,21种霉菌毒素的平均回收率为62.0％ ～ 116.4％,相对标准偏差小于19％.     

固相萃取-液质联用法同时测定饮用水中双酚A和邻苯二甲酸二丁酯

建立了饮用水中痕量双酚A和邻苯二甲酸二丁酯同时测定的LC/MS-MS快速分析方法.水样中双酚A和邻苯二甲酸二丁酯经HLB固相萃取小柱富集,以V(乙腈)∶V(水)＝90∶10为流动相,选择双酚A m/z 227/212、邻苯二甲酸二丁酯m/z 301/228为检测离子对,利用多反应监测(MRM)和扫描时间分段检测技术实现正、负离子不同扫描模式一次完成.该方法对水样体积为250 mL时双酚A和邻苯二甲酸二丁酯的线性范围为0.4～40 ng/L,检出限分别为0.16和0.10 ng/L,低中高3个不同水平的加标平均回收率均在90%以上.应用于5种不同来源的饮用水及原水中双酚A和邻苯二甲酸二丁酯的测定.     

超高效液相色谱-串联质谱法测定注射用头孢曲松钠中2-巯基苯并噻唑的含量

建立了一种超高效液相色谱-串联质谱法（UPLC-MS/MS）测定注射用头孢曲松钠中2-巯基苯并噻唑（MBT）基因毒性杂质含量。样品经甲醇提取,50%(V/V)乙腈稀释后,采用ACQUITY UPLC HSS T3色谱柱（2.1 mm×100 mm, 1.8μm）分离,乙腈-0.05%(V/V)乙酸（80∶20, V/V）为流动相,电喷雾离子源（ESI）,多反应监测（MRM）负离子模式扫描,外标法定量。MBT在0.11～10.92 ng/mL范围内线性关系良好（r2=0.9989）,检出限为0.03 ng/mL,定量限为0.08 ng/mL,平均回收率为96.8%,相对标准偏差（RSD）不大于3.5%。采用该方法检测抽检的14个厂家63批次样品中MBT杂质含量,59批次样品中有MBT检出。该方法适用于注射用头孢曲松钠中MBT的定性和定量分析。     

液相色谱-质谱法测定人体血浆中非那雄胺含量

建立了测定人体血浆中非那雄胺药物浓度的液相色谱-质谱分析方法。色谱柱为Hypersil-Keystone C_(18)柱,流动相为乙腈∶水(含0.2%三氯乙酸)=55∶45(V/V),质谱选择电喷雾正离子源(ESI+),选择离子模式(SIM)监测,非那雄胺和内标卡马西平质荷比分别为m/z373和m/z237。血浆样品经乙腈去蛋白、离心和吹干后,残渣用流动相溶解。当非那雄胺的浓度在0.5~120ng·mL~(-1)范围时线性关系良好(r=0.999),检测限(S/N=3)为0.02ng·mL~(-1);日间和日内测定的精密度(RSD)分别在6.4%~2.2%和5.5%~1.7%之间;加标0.5ng·mL~(-1)、40ng·mL~(-1)和80ng·mL~(-1)非那雄胺的平均回收率(n=6)分别为108.5%、101.2%和98.7%。方法快速、准确和灵敏,已成功用于人血浆中非那雄胺浓度的测定和人体药代动力学研究。     

高效液相色谱法测定恩替卡韦口服液中有关物质

建立了测定恩替卡韦口服液中有关物质的高效液相色谱法。采用Agilent ZORBAX SB-C18色谱柱,以水-乙腈-三氟乙酸(97∶3∶0.15,V/V)/乙腈为流动相,梯度洗脱,二极管阵列检测器(DAD)检测。杂质A、B和C的检测限分别为7.22ng/mL、7.30ng/mL和7.50ng/mL,分别相当于恩替卡韦浓度的0.014%、0.015%、0.015%;杂质A在24.08~361.0ng/mL浓度范围内(r=0.9988),杂质B在24.33~364.9ng/mL浓度范围内(r=0.9996),杂质C在25.00~375.0ng/mL浓度范围内(r=0.9984)呈现良好的线性关系;在0.125、0.25、0.37μg/mL三个浓度的添加水平下,杂质A、B、C的平均回收率分别为121.9%、115.5%和106.9%。     

A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study

A rapid and high sensitive liquid chromatography-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the quantification of zolpidem in human EDTA plasma using ondansetron (IS) as an internal standard. The analyte and IS were extracted from human plasma using ethyl acetate and separated on a C18 column (Inertsil-ODS, 5 μm, 4.6 × 50 mm) interfaced with a triple quadrupole tandem mass spectrometer. The mobile phase, which consisted of a mixture of methanol and 20 mM ammonium formate (pH 5.00 ± 0.05; 75:25 v/v), was injected at a flow rate of 0.40 mL/min. The retention times of zolpidem and IS were approximately 1.76 and 1.22. The LC run time was 3 min. The electrospray ionization source was operated in positive ion mode. Multiple reaction monitoring used the [M + H](+) ions m/z 308.13 → 235.21 for zolpidem and m/z 294.02 → 170.09 for the ondansetron, respectively. Five freeze-thaw cycles was established at -20 and -70°C.The linearity of the response/concentration curve was established in human EDTA plasma over the concentration range 0.10-149.83 ng/mL. The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL. This LC-MS-MS method was validated with intra-batch and inter-batch precision of 0.52-8.66.The intra-batch and inter-batch accuracy was 96.66-106.11. Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%. The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.     

A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma

A highly sensitive liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of midazolam and its major metabolites 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma was developed and validated. Stable isotope-labeled midazolam-D(4) and 1'-hydroxymidazolam-D(4) were used as internal standards. Compounds were extracted from 0.5 mL plasma by liquid-liquid extraction with ethyl acetate-heptane (1:4). Chromatography was achieved using a Sunfire C(18) column. The mobile phase was a gradient with 10 m m formic acid in Milli-Q water and methanol at a flow rate of 0.3 mL/min. Total run time was 10 min. Detection was performed using a tandem mass spectrometer with positive electrospray ionization. Calibration curves were linear over the range of 0.10-50.0 ng/mL for midazolam and 0.025-25.0 ng/mL for both metabolites. For all compounds the lower limit of quantification was 0.10 ng/mL. Imprecision was assessed according to the NCCLS EP5-T guideline and was below 10% for all compounds. Mean recoveries were between 94 and 109% for midazolam and its metabolites. The validated method was successfully applied in a pharmacokinetic study investigating in vivo CYP3A-activity in a large cohort of renal allograft recipients using sub-therapeutic doses of midazolam as a drug-probe.     

基质分散固相萃取-高效液相色谱/串联质谱法检测红薯中氯吡脲

建立了分散固相萃取-高效液相色谱/串联质谱法测定红薯中氯吡脲含量的分析方法.样品经分散剂(硅胶,C18HC)研磨分散提取,甲醇洗脱.采用Thermo Hypersil Gold C18色谱柱(150×2,1 mm,5μm)分离,以甲醇(A)/0.1％甲酸-5 mmol/L甲酸铵(B)作为流动相,梯度洗脱,采用串联质谱在正离子扫描方式下,通过选择反应模式定量分析,外标法定量.氯吡脲在2.63～675.00 ng/mL范围内线性关系良好,相关系数R2＞0.999.定量检测限为0.66 ng/mL.氯吡脲在10、25、50 ng/g三个浓度水平的添加回收率在70％～130％之间.该方法操作简单、准确,适用于红薯中氯吡脲的定量检测.     

Development and validation of a liquid chromatographic/tandem mass spectrometric method for the determination of sertraline in human plasma

A sensitive and rapid liquid chromatographic/tandem mass spectrometric method was developed and validated for the determination of sertraline in human plasma. The analyte and internal standard (IS, diphenhydramine) were extracted with 3 mL of diethyl ether/dichloromethane (2:1, v/v) from 0.25 mL plasma, then separated on a Zorbax Eclipse XDB C18 column using methanol/water/formic acid (75:25:0.1, v/v/v) as the mobile phase. The triple quadrupole mass spectrometry was applied via an atmospheric pressure chemical ionization (APCI) source for detection. The fragmentation pattern of the protonated sertraline was elucidated with the aid of product mass spectra of isotopologous peaks. Quantification was performed using selected reaction monitoring of the transitions of m/z 306 --> 159 for sertraline and m/z 256 --> 167 for the IS. The method was linear over the concentration range of 0.10-100 ng/mL. The intra-day and inter-day precisions, expressed by relative standard deviation, were both less than 6.7%. Assay accuracies were within +/-6.9% as terms of relative error. The lower limit of quantification (LLOQ) was identifiable and reproducible at 0.10 ng/mL with a precision of 8.3% and an accuracy of 9.6%. The validated method has been successfully applied for the pharmacokinetic study and bioequivalence evaluation of sertraline in 18 healthy volunteers after a single oral administration of 50 mg sertraline hydrochloride tablets.     

On-line desalting and determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in microdialysis and plasma samples using column switching and liquid chromatography/tandem mass spectrometry

A sensitive and reproducible method for the determination of morphine and the metabolites morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) was developed. The method was validated for perfusion fluid used in microdialysis as well as for sheep and human plasma. A C18 guard column was used to desalt the samples before analytical separation on a ZIC HILIC (hydrophilic interaction chromatography) column and detection with tandem mass spectrometry (MS/MS). The mobile phases were 0.05% trifluoroacetic acid (TFA) for desalting and acetonitrile/5 mM ammonium acetate (70:30) for separation. Microdialysis samples (5 microL) were directly injected onto the system. The lower limits of quantification (LLOQ) for morphine, M3G and M6G were 0.50, 0.22 and 0.55 ng/mL, respectively, and the method was linear from LLOQ to 200 ng/mL. For plasma, a volume of 100 microL was precipitated with acetonitrile containing internal standards (deuterated morphine and metabolites). The supernatant was evaporated and reconstituted in 0.05% TFA before the desalting process. The LLOQs for sheep plasma were 2.0 and 3.1 ng/mL and the ranges were 2.0-2000 and 3.1-3100 ng/mL for morphine and M3G, respectively. For human plasma, the LLOQs were 0.78, 1.49 and 0.53 ng/mL and the ranges were 0.78-500, 1.49-1000 and 0.53-500 ng/mL for morphine, M3G and M6G, respectively.     

Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry

A sensitive method using enantiospecific liquid chromatography/tandem mass spectrometry detection for the quantitation of S- and R-mephenytoin as well as its metabolites S- and R-nirvanol and S- and R-4'-hydroxymephenytoin in plasma and urine has been developed and validated. Plasma samples were prepared by protein precipitation with acetonitrile, while urine samples were diluted twice with the mobile phase before injection. The analytes were then separated on a chiral alpha(1)-acid glycoprotein (AGP) column and thereafter detected, using electrospray ionization tandem mass spectrometry. In plasma, the lower limit of quantification (LLOQ) was 1 ng/mL for S- and R-4'-hydroxymephenytoin and S-nirvanol and 3 ng/mL for R-nirvanol and S- and R-mephenytoin. In urine, the LLOQ was 3 ng/mL for all compounds. Resulting plasma and urine intra-day precision values (CV) were <12.4% and <6.4%, respectively, while plasma and urine accuracy values were 87.2-108.3% and 98.9-104.8% of the nominal values, respectively. The method was validated for plasma in the concentration ranges 1-500 ng/mL for S- and R-4'-hydroxymephenytoin, 1-1000 ng/mL for S-nirvanol, and 3-1500 ng/mL for R-nirvanol and S- and R-mephenytoin. The validated concentration range in urine was 3-5000 ng/mL for all compounds. By using this method, the metabolic activities of two human drug-metabolizing enzymes, cytochrome P450 (CYP) 2C19 and CYP2B6, were simultaneously characterized.     

A highly sensitive LC-tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers

The new-generation nebulizers are commonly used for the administration of salbutamol in mechanically ventilated patients. The different modes of administration and new devices have not been compared. We developed a liquid chromatography-tandem mass spectrometry method for the determination of concentrations as low as 0.05 ng/mL of salbutamol, corresponding to the desired plasma concentration after inhalation. Salbutamol quantification was performed by reverse-phase HPLC. Analyte quantification was performed by electrospray ionization-triple quadrupole mass spectrometry using selected reaction monitoring detection ESI in the positive mode. The method was validated over concentrations ranging from 0.05 to 100 ng/mL in plasma and from 0.18 to 135 ng/mL in urine. The method is precise, with mean inter-day coefficient of variation (CV%) within 3.1-8.3% in plasma and 1.3-3.9% in urine, as well as accurate. The proposed method was found to reach the required sensitivity for the evaluation of different nebulizers as well as nebulization modes. The present assay was applied to examine whether salbutamol urine levels, normalized with the creatinine levels, correlated with the plasma concentrations. A suitable, convenient and noninvasive method of monitoring patients receiving salbutamol by mechanical ventilation could be implemented.     

Quantitative determination of medroxyprogesterone acetate in plasma by liquid chromatography/electrospray ion trap mass spectrometry.

A sensitive and rapid liquid chromatography/electrospray ion trap mass spectrometry (LC/MS/MS) method has been developed for the quantitative determination of medroxyprogesterone acetate (MPA) in human plasma. Plasma samples (1.0 mL) were simply extracted with pentane and the extracts were analyzed by HPLC with the detection of the analyte in the selective reaction monitoring (SRM) mode. The determination of MPA was accurate and reproducible, with a limit of quantitation of 0.05 ng/mL in plasma. The standard calibration curve for MPA was linear (r = 0.998) over the concentration range 0.05-6.0 ng/mL in human plasma. Analysis precision over the concentration range of MPA was lower than 18.8% (relative standard deviation, RSD) and accuracy was between 96.2 and 108.7%.